Epidemiology of Resistant Hypertension
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
J Clin Hypertens (Greenwich). 2011;13:523–528. ©2011 Wiley Periodicals, Inc. Resistant hypertension is an entity that has gained a lot of attention in recent years. The prevalence and prognosis of resistant hypertension have not yet been examined by proper population studies, but data from several sources suggest that this entity is not uncommon and is associated with an elevated risk of hypertensive complications. Moreover, several factors and conditions that can interfere with blood pressure control such as excess sodium intake, obesity, diabetes, older age, kidney disease, and certain identifiable causes of hypertension were shown to be common among patients with resistance to antihypertensive treatment. Importantly, the prevalence of several of these conditions has been increasing continuously during the past years, suggesting a future increase in the frequency of resistant hypertension. This article will discuss current knowledge and associated future implications relevant to the epidemiology of resistant hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491 · cited 1×
“However, the benefits of successful treatment in these individuals are likely to be substantial, as evidenced by major outcome studies in the field, where the greater the baseline BP levels and ⁄ or the larger the decrease in BP, the greater the reductions in hypertension-associated target organ damage.(30,31) PATIENT…”
BackgroundBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · cited 1×
“However, for these control rates to be possible, about 60% of participants had to receive maximal doses of combination therapy at 6 months, and 32% of them to be taking 3 drugs after 1 year of follow-up.(24) All these studies also suggest that resistant hypertension is not uncommon.”
BackgroundPrevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999–2004
Ong, K. L., Cheung, B. M. Y., Man, Y. B., Lau, C. P., & Lam, K. S. L. (2007) · Hypertension · doi:10.1161/01.hyp.0000252676.46043.18 · Cited by 1,395
Alonso, A., Lau, J., Jaber, B. L., Weintraub, A., & Sarnak, M. J. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2003.09.009 · Cited by 345
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
BRAMLAGE, P., PITTROW, D., WITTCHEN, H., KIRCH, W., BOEHLER, S., LEHNERT, H., HOEFLER, M., UNGER, T., & SHARMA, A. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.05.017 · Cited by 328 · cited 1×
“Increased body weight is also associated with more severe hypertension, need for an increased number of antihypertensive medications, and a decreased likelihood of achieving BP control.(40) Obesity contributes to BP elevation through various mechanisms, such as insulin resistance ⁄ hyperinsulinemia, impaired sodium ex…”
BackgroundHigh prevalence of cardiac and extracardiac target organ damage in refractory hypertension
Cuspidi, C., Macca, G., Sampieri, L., Michev, I., Salerno, M., Fusi, V., Severgnini, B., Meani, S., Magrini, F., & Zanchetti, A. (2001) · Journal of Hypertension · doi:10.1097/00004872-200111000-00018 · Cited by 303
Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension
Salles, G. F., Cardoso, C. R. L., & Muxfeldt, E. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2340 · Cited by 293
Aldosterone Excretion Among Subjects With Resistant Hypertension and Symptoms of Sleep Apnea
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., & Harding, S. M. (2004) · Chest · doi:10.1378/chest.125.1.112 · Cited by 260
Cited by
Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,215
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Apparent and true resistant hypertension: definition, prevalence and outcomes
Judd, E., & Calhoun, D. A. (2014) · Journal of Human Hypertension · doi:10.1038/jhh.2013.140 · Cited by 277
Sim, J. J., Bhandari, S. K., Shi, J., Reynolds, K., Calhoun, D. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2015) · Kidney International · doi:10.1038/ki.2015.142 · Cited by 238
Sim, J. J., Bhandari, S. K., Shi, J., Liu, I. L. A., Calhoun, D. A., McGlynn, E. A., Kalantar-Zadeh, K., & Jacobsen, S. J. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.06.017 · Cited by 206
Metadata
- Authors
- Sarafidis, P. A.
- Venue
- The Journal of Clinical Hypertension
- Publisher
- Wiley
- Published
- 2011-03-28
- Volume
- 13
- Issue
- 7
- Pages
- 523-528
- ISSN
- 1524-6175 (ISSN-L)
- 1751-7176
- OpenAlex
- W1536186020
- Cited by
- 73
- References
- 12
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidemiology of Resistant Hypertension. https://app.cochat.ai/papers/10.1111/j.1751-7176.2011.00445.x
- The paper
- Sarafidis, P. A. (2011). Epidemiology of Resistant Hypertension. The Journal of Clinical Hypertension. https://doi.org/10.1111/j.1751-7176.2011.00445.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.